Annual CFI
$168.00 M
+$459.65 M+157.60%
December 31, 2023
Summary
- As of February 7, 2025, RARE annual cash flow from investing activities is $168.00 million, with the most recent change of +$459.65 million (+157.60%) on December 31, 2023.
- During the last 3 years, RARE annual CFI has risen by +$347.12 million (+193.79%).
- RARE annual CFI is now at all-time high.
Performance
RARE Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$275.50 M
-$336.07 M-554.89%
September 30, 2024
Summary
- As of February 7, 2025, RARE quarterly cash flow from investing activities is -$275.50 million, with the most recent change of -$336.07 million (-554.89%) on September 30, 2024.
- Over the past year, RARE quarterly CFI has dropped by -$339.80 million (-528.50%).
- RARE quarterly CFI is now -347.52% below its all-time high of $111.30 million, reached on March 31, 2023.
Performance
RARE Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$227.52 M
-$339.80 M-302.64%
September 30, 2024
Summary
- As of February 7, 2025, RARE TTM cash flow from investing activities is -$227.52 million, with the most recent change of -$339.80 million (-302.64%) on September 30, 2024.
- Over the past year, RARE TTM CFI has dropped by -$330.94 million (-320.00%).
- RARE TTM CFI is now -235.43% below its all-time high of $168.00 million, reached on December 31, 2023.
Performance
RARE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
RARE Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +157.6% | -528.5% | -320.0% |
| 3 y3 years | +193.8% | -575.9% | -36.6% |
| 5 y5 years | +604.0% | -447.4% | -1644.9% |
RARE Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +157.6% | -347.5% | at low | -235.4% | +22.0% |
| 5 y | 5-year | at high | +157.6% | -347.5% | at low | -235.4% | +22.0% |
| alltime | all time | at high | +157.5% | -347.5% | at low | -235.4% | +22.2% |
Ultragenyx Pharmaceutical Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$275.50 M(-554.9%) | -$227.52 M(-302.6%) |
| Jun 2024 | - | $60.56 M(-35.9%) | $112.28 M(-25.7%) |
| Mar 2024 | - | $94.44 M(-188.2%) | $151.13 M(-10.0%) |
| Dec 2023 | $168.00 M(-157.6%) | -$107.02 M(-266.4%) | $168.00 M(+62.4%) |
| Sep 2023 | - | $64.30 M(-35.3%) | $103.42 M(-184.3%) |
| Jun 2023 | - | $99.42 M(-10.7%) | -$122.74 M(-14.2%) |
| Mar 2023 | - | $111.30 M(-164.9%) | -$142.99 M(-51.0%) |
| Dec 2022 | -$291.65 M(+49.3%) | -$171.60 M(+6.0%) | -$291.65 M(+471.9%) |
| Sep 2022 | - | -$161.86 M(-304.5%) | -$51.00 M(-172.7%) |
| Jun 2022 | - | $79.17 M(-311.9%) | $70.10 M(-239.3%) |
| Mar 2022 | - | -$37.36 M(-154.1%) | -$50.31 M(-74.2%) |
| Dec 2021 | -$195.37 M(+9.1%) | $69.06 M(-269.4%) | -$195.37 M(+17.3%) |
| Sep 2021 | - | -$40.76 M(-1.2%) | -$166.53 M(-24.8%) |
| Jun 2021 | - | -$41.25 M(-77.4%) | -$221.53 M(-16.9%) |
| Mar 2021 | - | -$182.42 M(-286.3%) | -$266.42 M(+48.7%) |
| Dec 2020 | -$179.12 M(+1273.7%) | $97.90 M(-202.2%) | -$179.12 M(-14.6%) |
| Sep 2020 | - | -$95.76 M(+11.2%) | -$209.76 M(+504.8%) |
| Jun 2020 | - | -$86.14 M(-9.4%) | -$34.68 M(+397.5%) |
| Mar 2020 | - | -$95.13 M(-241.4%) | -$6.97 M(-46.5%) |
| Dec 2019 | -$13.04 M(-60.9%) | $67.27 M(-15.2%) | -$13.04 M(+93.3%) |
| Sep 2019 | - | $79.31 M(-235.8%) | -$6.74 M(-90.3%) |
| Jun 2019 | - | -$58.43 M(-42.3%) | -$69.85 M(+10.0%) |
| Mar 2019 | - | -$101.19 M(-237.6%) | -$63.50 M(+90.5%) |
| Dec 2018 | -$33.33 M | $73.56 M(+353.9%) | -$33.33 M(-32.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $16.20 M(-131.1%) | -$49.50 M(+37.8%) |
| Jun 2018 | - | -$52.07 M(-26.7%) | -$35.92 M(+629.2%) |
| Mar 2018 | - | -$71.03 M(-223.8%) | -$4.93 M(-108.9%) |
| Dec 2017 | $55.48 M(-39.1%) | $57.39 M(+92.7%) | $55.48 M(-712.2%) |
| Sep 2017 | - | $29.79 M(-241.3%) | -$9.06 M(-166.3%) |
| Jun 2017 | - | -$21.08 M(+98.5%) | $13.66 M(-76.7%) |
| Mar 2017 | - | -$10.62 M(+48.5%) | $58.72 M(-35.6%) |
| Dec 2016 | $91.12 M(-131.2%) | -$7.15 M(-113.6%) | $91.12 M(+40.8%) |
| Sep 2016 | - | $52.51 M(+118.9%) | $64.71 M(-149.2%) |
| Jun 2016 | - | $23.99 M(+10.2%) | -$131.51 M(-50.7%) |
| Mar 2016 | - | $21.77 M(-164.9%) | -$266.51 M(-8.8%) |
| Dec 2015 | -$292.35 M(+136.8%) | -$33.56 M(-76.6%) | -$292.35 M(+6.0%) |
| Sep 2015 | - | -$143.72 M(+29.5%) | -$275.81 M(+89.4%) |
| Jun 2015 | - | -$111.01 M(+2630.9%) | -$145.64 M(+134.5%) |
| Mar 2015 | - | -$4.07 M(-76.1%) | -$62.11 M(-49.7%) |
| Dec 2014 | -$123.44 M(+158.6%) | -$17.02 M(+25.7%) | -$123.44 M(+29.5%) |
| Sep 2014 | - | -$13.54 M(-50.7%) | -$95.31 M(+15.5%) |
| Jun 2014 | - | -$27.48 M(-58.0%) | -$82.55 M(-15.8%) |
| Mar 2014 | - | -$65.40 M(-688.5%) | -$98.03 M(+105.4%) |
| Dec 2013 | -$47.73 M(+3907.9%) | $11.11 M(-1512.1%) | -$47.73 M(-18.9%) |
| Sep 2013 | - | -$787.00 K(-98.2%) | -$58.85 M(+1.4%) |
| Jun 2013 | - | -$42.96 M(+184.5%) | -$58.06 M(+284.5%) |
| Mar 2013 | - | -$15.10 M | -$15.10 M |
| Dec 2012 | -$1.19 M(+28.9%) | - | - |
| Dec 2011 | -$924.00 K | - | - |
FAQ
- What is Ultragenyx Pharmaceutical annual cash flow from investing activities?
- What is the all time high annual CFI for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual CFI year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly CFI year-on-year change?
- What is Ultragenyx Pharmaceutical TTM cash flow from investing activities?
- What is the all time high TTM CFI for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM CFI year-on-year change?
What is Ultragenyx Pharmaceutical annual cash flow from investing activities?
The current annual CFI of RARE is $168.00 M
What is the all time high annual CFI for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual cash flow from investing activities is $168.00 M
What is Ultragenyx Pharmaceutical annual CFI year-on-year change?
Over the past year, RARE annual cash flow from investing activities has changed by +$459.65 M (+157.60%)
What is Ultragenyx Pharmaceutical quarterly cash flow from investing activities?
The current quarterly CFI of RARE is -$275.50 M
What is the all time high quarterly CFI for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly cash flow from investing activities is $111.30 M
What is Ultragenyx Pharmaceutical quarterly CFI year-on-year change?
Over the past year, RARE quarterly cash flow from investing activities has changed by -$339.80 M (-528.50%)
What is Ultragenyx Pharmaceutical TTM cash flow from investing activities?
The current TTM CFI of RARE is -$227.52 M
What is the all time high TTM CFI for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM cash flow from investing activities is $168.00 M
What is Ultragenyx Pharmaceutical TTM CFI year-on-year change?
Over the past year, RARE TTM cash flow from investing activities has changed by -$330.94 M (-320.00%)